– Treatment with sotatercept in the ongoing SPECTRA Phase 2 trial was associated with improvements in resting and exercise hemodynamics at week 24 – – Sotatercept was generally well tolerated, consistent with the previously reported safety profile in PAH and in other diseases – – Company-hosted investor and analyst conference call and webcast with guest […]